Towards a dengue vaccine: Progress to date and remaining challenges

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 31, Issue 2-3, 2008, Pages 239-252

  Guy, Bruno ^a   Almond, Jeffrey W ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Antibodies; Cellular immunity; Clinical trials; Dengue; Vaccine; Vaccine safety

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; BETA INTERFERON; CHIMERIVAX; DENGUE VACCINE; DNA VACCINE; GAMMA INTERFERON; INACTIVATED VIRUS VACCINE; INTERFERON RECEPTOR; INTERLEUKIN 6; LIVE VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; INNATE IMMUNITY; NONHUMAN; PREVALENCE; SEROCONVERSION; SINGLE DRUG DOSE; VACCINATION; VACCINE PRODUCTION; VIRAL GENE THERAPY; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

DENGUE VIRUS;

EID: 39849090021     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2007.07.011     Document Type: Article

References (46)

1. B. Adams E.C. Holmes C. Zhang M.P. Mammen Jr. S. Nimmannitya S. Kalayanarooj Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok Proc Natl Acad Sci USA 103 2006 14234 14239
2. D.W. Vaughn S. Green S. Kalayanarooj B.L. Innis S. Nimmannitya S. Suntayakorn Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity J Infect Dis 181 2000 2 9
3. A.L. Rothman Dengue: defining protective versus pathologic immunity J Clin Invest 113 7 2004 946 951
4. S. Green A. Rothman Immunopathological mechanisms in dengue and dengue hemorrhagic fever Curr Opin Infect Dis 19 2006 429 436
5. S.B. Halstead E.J. O’Rourke Antibody-enhanced dengue virus infection in primate leukocytes Nature 265 1977 739 741
6. S.C. Kliks A. Nisalak W.E. Brandt L. Wahl D. Burke Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever Am J Trop Med Hyg 40 1989 444 451
7. J.G. Rigau-Perez G.G. Clark D.J. Gubler P. Reiter E.J. Sanders A.V. Vorndam Dengue and dengue haemorrhagic fever Lancet 352 1998 971 977
8. M.G. Guzman G. Kouri Dengue: an update Lancet Infect Dis 2 2002 33 42
9. J.L. Deen E. Harris B. Wills A. Balmaseda S.N. Hammond C. Rocha The WHO dengue classification and case definitions: time for a reassessment Lancet 368 2006 170 173
10. J. Almond J. Clemens H. Engers S. Halstead H.B. Khiem A. Pablos-Mendez Accelerating the development and introduction of a dengue vaccine for poor children, 5–8 December 2001, Ho Chi Minh City, VietNam Vaccine 20 2002 3043 3046
11. M. Marovich G. Grouard-Vogel M. Louder M. Eller W. Sun S.J. Wu Human dendritic cells as targets of dengue virus infection Inves Dermatol Symp Proc 6 3 2001 219 224
12. T.P. Endy A. Nisalak S. Chunsuttitwat D.W. Vaughn S. Green F.A. Ennis Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand J Infect Dis 189 2004 990 1000
13. K. Laoprasopwattana D.H. Libraty T.P. Endy A. Nisalak S. Chunsuttiwat D.W. Vaughn Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection J Infect Dis 192 2005 510 519
14. B. Guy P. Chanthavanich S. Gimenez C. Sirivichayakul A. Sabchareon S. Begue Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine Vaccine 22 2004 3563 3574
15. A. Sabchareon J. Lang P. Chanthavanich S. Yoksan R. Forrat P. Attanath Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses Am J Trop Med Hyg 66 2002 264 272
16. A. Sabchareon J. Lang P. Chanthavanich S. Yoksan R. Forrat P. Attanath Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children Pediatr Infect Dis J 23 2004 99 109
17. F. Guirakhoo S. Kitchener D. Morrison R. Forrat K. McCarthy R. Nichols Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes Hum Vaccine 2 2006 60 67
18. Luhn K, Simmons CP, Moran E, Dung NT, Chau TN, Quyen NT, et al. Increased frequencies of CD4+CD25high regulatory T cells in acute dengue infection. J Exp Med 2007.
19. A.L. Rothman F.A. Ennis Immunopathogenesis of dengue hemorrhagic fever Virology 257 1999 1 6
20. M. Simmons K.R. Porter C.G. Hayes D.W. Vaughn R. Putnak Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques J Virol 80 2006 9577 9585
21. S. Khanam P. Rajendra N. Khanna S. Swaminathan An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes BMC Biotechnol 7 2007 10 17
22. B.L. Innis K.H. Eckels Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command Am J Trop Med Hyg 69 2003 1 4
23. K.H. Eckels D.R. Dubois R. Putnak D.W. Vaughn B.L. Innis E.A. Henchal Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys Am J Trop Med Hyg 69 6 Suppl 2003 12 16
24. V. Sanchez S. Gimenez B. Tomlinson P.K. Chan G.N. Thomas R. Forrat Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3) Vaccine 24 2006 4914 4926
25. R. Men M. Bray D. Clark R.M. Chanock C.J. Lai Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys J Virol 70 1996 3930 3937
26. S.S. Whitehead A live, attenuated Dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys J Virol 77 2003 1653 1657
27. J.E. Blaney A.P. Durbin B.R. Murphy S.S. Whitehead Development of a live attenuated dengue virus vaccine using reverse genetics Viral Immunol 19 2006 10 32
28. F. Guirakhoo J. Arroyo K.V. Pugachev C. Miller Z.X. Zhang R. Weltzin Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine J Virol 75 2001 7290 7304
29. J. Putnak R B.A. Coller G. Voss D.W. Vaughn D. Clements I. Peters An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model Vaccine 23 2005 4442 4452
30. S. Khanam B. Etemad N. Khanna S. Swaminathan Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes Am J Trop Med Hyg 74 2006 266 277
31. R. Putnak K. Porter C. Schmaljohn DNA vaccines for flaviviruses Adv Virus Res 61 2003 445 468
32. D.H. Holman D. Wang K. Raviprakash N.U. Raja M. Luo J. Zhang Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes Clin Vaccine Immunol 14 2007 182 189
33. S. Kitchener M. Nissen P. Nasveld R. Forrat S. Yoksan J. Lang Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults Vaccine 24 2006 1238 1241
34. K. Raviprakash D. Apt A. Brinkman C. Skinner S. Yang G. Dawes A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques Virology 353 2006 166 173
35. D. Apt K. Raviprakash A. Brinkman A. Semyonov S. Yang C. Skinner Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen Vaccine 24 2006 335 344
36. WHO Technical report series, No. 872, 1998.
37. F. Guirakhoo K. Pugachev Z. Zhang G. Myers I. Levenbook K. Draper Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates J Virol 78 2004 4761 4775
38. S. Shresta J.L. Kyle H.M. Snider M. Basavapatna P.R. Beatty E. Harris Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical J Virol 78 2004 2701 2710
39. S. Shresta K.L. Sharar D.M. Prigozhin P.R. Beatty E. Harris Murine model for dengue virus-induced lethal disease with increased vascular permeability J Virol 80 2006 10208 10217
40. D.H. Libraty S. Pichyangkul C. Ajariyakhajorn T.P. Endy F.A. Ennis Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis J Virol 75 2001 3501 3508
41. D.R. Palmer P. Sun C. Celluzzi J. Bisbing S. Pang W. Sun Differential effects of dengue virus on infected and bystander dendritic cells J Virol 79 4 2005 2432 2439
42. V. Sanchez C. Hessler A. DeMonfort J. Lang B. Guy Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with dengue 2 live-attenuated vaccine or 16681 parental strain FEMS Immunol Med Microbiol 46 2006 113 123
43. F. Deauvieau V. Sanchez C. Balas A. Kennel A. de Montfort J. Lang Innate immune responses in human dendritic cells upon infection by chimeric Yellow fever Dengue vaccines serotype 1 to 4 Am J Trop Med Hyg 76 2007 144 154
44. S. Higgs D.L. Vanlandingham K.A. Klingler K.L. McElroy C.E. McGee L. Harrington Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand Am J Trop Med Hyg 75 2006 986 993
45. P. Chanthavanich C. Luxemburger C. Sirivichayakul K. Lapphra K. Pengsaa S. Yoksan Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine Am J Trop Med Hyg 75 2006 26 28
46. A.L. Rothman N. Kanesa-thasan K. West J. Janus J.F. Saluzzo F.A. Ennis Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine Vaccine 19 2001 4694 4699